BA Research Update — September 10, 2026 (Updated)

Updated Thesis

Boeing is a global aerospace and defense manufacturer spanning commercial airliners, military aircraft, satellites, missile defense, and aftermarket services, with roughly 182,000 employees and a business that remains structurally advantaged by the duopoly economics of large commercial aircraft and the long-cycle, high-switching-cost nature of aerospace platforms. The business quality is currently impaired rather than absent: TTM gross margin is just 4.7%, TTM operating margin is -5.4%, and TTM net margin is 2.6%, while free cash flow per share is negative $0.27 and first-half 2026 free cash flow was negative $823 million even though quarterly free cash flow turned positive at $631 million in 2Q 2026. Revenue growth of 8.0% and earnings growth of 27.3% in the most recent quarter show the recovery is underway, and the balance sheet has improved with debt falling to $45.9 billion at June 30, 2026 from $54.1 billion at December 31, 2025.

The investment grade as of this refresh is B — solid business quality. Medium-tier business, cheap-tier valuation with 31.7% upside to $265 fair value.

Key Metrics at a Glance

Current price: $201.15

These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.

Our 12–18 Month Outlook

Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Boeing Company remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.

Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.

[View full BA research →](/stocks/BA)